Skip to main content

Johnson & Johnson Cardiovascular revenue

  • JNJ · NYSE
  • Healthcare
  • Pharmaceuticals
  • S&P 500
$285.75+0.79%Close 13 Nov 2026 · Market value $684.4B

Cardiovascular revenue at Johnson & Johnson came to $2.3B for the quarter to 27 Sep 2026, up 4.2% from a year earlier.

As Johnson & Johnson reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 21 Oct 2026.

By quarter

$2.3BJun 2025$2.2BSep 2025$2.4BJun 2026$2.3BSep 2026
Johnson & Johnson Cardiovascular revenue, every reported period
Period endingCardiovascular revenueChange on a yearFiled
27 Sep 2026$2.3Bup 4.2%21 Oct 2026
28 Jun 2026$2.4Bup 3.9%23 Jul 2026
28 Sep 2025$2.2B—22 Oct 2025
29 Jun 2025$2.3B—24 Jul 2025

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Johnson & Johnson: MedTech worldwide operational sales (change on a year) · Oncology revenue · Immunology revenue · Neuroscience revenue · Pulmonary Hypertension revenue · Cardiovascular/Metabolism/Other revenue · Infectious Diseases revenue · Shockwave revenue · Innovative Medicine revenue · MEDTECH revenue · United States revenue · Non-US revenue · Europe revenue · Asia-Pacific, Africa revenue · Western Hemisphere, excluding U.S. revenue · financial statements

Every KPI and segment of JNJ, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.